Despite the recommendations of the SCC, a number of investigations demonstrated that (a) the administration of IvIg are associated with the reduction of the mortality of patients with sepsis and sepsis-related conditions [11–14],; and (b) IvIg preparations containing IgM and IgA are more effective than those containing IgG alone [15–18]. The gene discussed is CD40LG; the disease is Sepsis.